PTC Therapeutics Inc (PTCT)

Oct 31, 2026

PTC Therapeutics (PTCT) stock slid approximately 7% after the company reported Q3 2026 results, returning to a quarterly loss despite a significant increase in total revenue to US$358 million, primarily driven by Sephience. While the company boasts US$2.13 billion in cash and raised its 2026 guidance for product and total revenue, investors reacted negatively to the shift from profit to loss, overshadowing the growth in its rare disease franchise and progress on pipeline milestones.

Oct 30, 2026

PTC Therapeutics reported record Q3 2026 product revenue of $276 million, driving a raise in full-year 2026 revenue guidance to $1.29 to $1.32 billion, primarily due to the strong global launch and continued growth of Cephiance. The company is advancing its pipeline with the acquisition of a BLA-stage Fabry disease gene therapy asset, ST920, and progression in Huntington's disease and Friedrich's ataxia programs. PTC Therapeutics anticipates achieving cash flow breakeven in 2026 and plans to leverage its significant cash reserves for further strategic initiatives and business development opportunities.